NF2 and schwannoma: mTOR signaling has also been experimentally demonstrated to be dysregulated in NF2-associated schwannomas, and clinical trials with mTOR inhibitors such as everolimus and sirolimus have shown efficacy in reducing the growth of tumors in NF2 patients [69, 70].